Ind-Swift Laboratories Limited (INDSWFTLAB) - Total Liabilities
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has total liabilities worth Rs2.37 Billion INR (≈ $25.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ind-Swift Laboratories Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. See Ind-Swift Laboratories Limited short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Ind-Swift Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oando PLC
JSE:OAO
|
South Africa | ZAC7.26 Trillion |
|
Ilyang Pharm
KO:007570
|
Korea | ₩205.41 Billion |
|
Acme United Corporation
NYSE MKT:ACU
|
USA | $78.52 Million |
|
Immunic Inc
NASDAQ:IMUX
|
USA | $30.73 Million |
|
Pinago Utama Tbk Pt
JK:PNGO
|
Indonesia | Rp545.29 Billion |
|
Prospect Resources Ltd
AU:PSC
|
Australia | AU$1.38 Million |
|
MAX Automation SE
XETRA:MXHN
|
Germany | €155.73 Million |
|
Quanterix Corp
NASDAQ:QTRX
|
USA | $129.61 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Ind-Swift Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ind-Swift Laboratories Limited market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.91 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ind-Swift Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual total liabilities of Ind-Swift Laboratories Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs2.65 Billion ≈ $28.70 Million |
-59.07% |
| 2024-03-31 | Rs6.48 Billion ≈ $70.12 Million |
-43.23% |
| 2023-03-31 | Rs11.42 Billion ≈ $123.52 Million |
-4.82% |
| 2022-03-31 | Rs12.00 Billion ≈ $129.77 Million |
-1.24% |
| 2021-03-31 | Rs12.15 Billion ≈ $131.40 Million |
-1.17% |
| 2020-03-31 | Rs12.29 Billion ≈ $132.95 Million |
-7.99% |
| 2019-03-31 | Rs13.36 Billion ≈ $144.50 Million |
-9.09% |
| 2018-03-31 | Rs14.70 Billion ≈ $158.95 Million |
-8.49% |
| 2017-03-31 | Rs16.06 Billion ≈ $173.70 Million |
-5.62% |
| 2016-03-31 | Rs17.02 Billion ≈ $184.04 Million |
+3.18% |
| 2015-03-31 | Rs16.49 Billion ≈ $178.36 Million |
+3.44% |
| 2014-03-31 | Rs15.94 Billion ≈ $172.43 Million |
+4.85% |
| 2013-03-31 | Rs15.21 Billion ≈ $164.45 Million |
+9.12% |
| 2012-03-31 | Rs13.94 Billion ≈ $150.71 Million |
+20.64% |
| 2011-03-31 | Rs11.55 Billion ≈ $124.92 Million |
+39.84% |
| 2010-03-31 | Rs8.26 Billion ≈ $89.33 Million |
+38.36% |
| 2009-03-31 | Rs5.97 Billion ≈ $64.56 Million |
+26.40% |
| 2008-03-31 | Rs4.72 Billion ≈ $51.08 Million |
+22.27% |
| 2007-03-31 | Rs3.86 Billion ≈ $41.78 Million |
+20.02% |
| 2006-03-31 | Rs3.22 Billion ≈ $34.81 Million |
-- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more